Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:BLPH NASDAQ:DFFN NYSEAMERICAN:OGEN NASDAQ:PCSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.80-2.9%$0.84$0.51▼$1.16$79.31M0.28248,339 shs138,344 shsBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shs7,027 shsDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsOGENOragenics$1.26-3.1%$1.21$1.01▼$18.90$5.37M0.83243,528 shs65,516 shsPCSAHeatwurx$0.31-15.0%$0.24$0.15▼$1.50$18.13M1.5324.30 million shs5.97 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-2.90%-4.17%-15.46%+18.90%-29.19%BLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%-66.67%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%0.00%OGENOragenics-3.08%-3.08%0.00%-6.67%-87.52%PCSAHeatwurx-15.02%-19.22%+47.97%+43.66%-76.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.80-2.9%$0.84$0.51▼$1.16$79.31M0.28248,339 shs138,344 shsBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shs7,027 shsDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsOGENOragenics$1.26-3.1%$1.21$1.01▼$18.90$5.37M0.83243,528 shs65,516 shsPCSAHeatwurx$0.31-15.0%$0.24$0.15▼$1.50$18.13M1.5324.30 million shs5.97 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio-2.90%-4.17%-15.46%+18.90%-29.19%BLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%-66.67%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%0.00%OGENOragenics-3.08%-3.08%0.00%-6.67%-87.52%PCSAHeatwurx-15.02%-19.22%+47.97%+43.66%-76.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.25Hold$2.38196.80% UpsideBLPHBellerophon Therapeutics 0.00N/AN/AN/ADFFNDiffusion Pharmaceuticals 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/APCSAHeatwurx 2.00Hold$1.00226.80% UpsideCurrent Analyst Ratings BreakdownLatest OGEN, BLPH, PCSA, ASRT, and DFFN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/8/2025ASRTAssertioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PCSAHeatwurxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ASRTAssertioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PCSAHeatwurxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/2/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.00 ➝ $1.008/26/2025PCSAHeatwurxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.50 ➝ $3.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.62$0.05 per share16.79$1.27 per share0.63BLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04DFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AOGENOragenics$40K130.10N/AN/A($0.51) per share-2.47PCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A26.67N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/AN/AN/AN/ADFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AOGENOragenics-$10.57M-$21.42N/A∞N/AN/A-3,614.27%-324.80%N/APCSAHeatwurx-$11.85M-$2.32N/AN/AN/AN/A-342.36%-243.48%10/29/2025 (Estimated)Latest OGEN, BLPH, PCSA, ASRT, and DFFN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/10/2025Q3 2025ASRTAssertio-$0.08N/AN/AN/A$27.02 millionN/A10/29/2025Q3 2025PCSAHeatwurx-$0.08N/AN/AN/AN/AN/A8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 million8/7/2025Q2 2025PCSAHeatwurx-$0.23-$0.25-$0.02-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34BLPHBellerophon TherapeuticsN/AN/AN/ADFFNDiffusion PharmaceuticalsN/A10.7110.71OGENOragenicsN/A0.500.50PCSAHeatwurxN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%BLPHBellerophon Therapeutics10.61%DFFNDiffusion Pharmaceuticals9.95%OGENOragenics18.71%PCSAHeatwurx91.93%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%BLPHBellerophon Therapeutics5.20%DFFNDiffusion Pharmaceuticals1.80%OGENOragenics4.90%PCSAHeatwurx2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableOGENOragenics54.13 million3.93 millionN/APCSAHeatwurx2050.35 million49.14 millionNot OptionableOGEN, BLPH, PCSA, ASRT, and DFFN HeadlinesRecent News About These CompaniesProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for GastroparesisJune 17, 2025 | quiverquant.comQProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceFebruary 7, 2025 | globenewswire.comProcessa Pharmaceuticals Closes $5 Million Public Offering with CEO and Institutional Investor ParticipationJanuary 30, 2025 | quiverquant.comQProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.comProcessa Pharmaceuticals director David Young buys $99,288 in stockJanuary 30, 2025 | msn.comProcessa Pharmaceuticals' chief business officer buys $34,691 in stockJanuary 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGEN, BLPH, PCSA, ASRT, and DFFN Company DescriptionsAssertio NASDAQ:ASRT$0.80 -0.02 (-2.90%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.82 +0.02 (+3.10%) As of 10/17/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Bellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Diffusion Pharmaceuticals NASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Oragenics NYSEAMERICAN:OGEN$1.26 -0.04 (-3.08%) Closing price 10/17/2025 04:10 PM EasternExtended Trading$1.25 -0.01 (-0.48%) As of 10/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Heatwurx NASDAQ:PCSA$0.31 -0.05 (-15.02%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+0.65%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
